Yan Leyfman: Discussing Artificial Intelligence in Lymphoma Immunotherapy

Yan Leyfman: Discussing Artificial Intelligence in Lymphoma Immunotherapy

Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:

“The future of cancer care will be shaped not only by scientific discovery, but by our ability to translate innovation into meaningful impact for patients.

It was a privilege to join colleagues from around the world at Technology Networks’ The Landscape of Cancer Research: Advances in Immuno-Oncology 2026 symposium, where I had the opportunity to discuss Artificial Intelligence in Lymphoma Immunotherapy and share our ongoing work exploring how AI can enhance clinical decision-making, accelerate research, and improve access to precision oncology.

The conversation reinforced a reality that is becoming increasingly clear: the most transformative advances in cancer care will emerge at the intersection of human expertise, immunotherapy, data science, and artificial intelligence.

Thank you to the Technology Networks team and symposium organizers for the invitation and for convening such an outstanding group of thought leaders. The exchange of ideas throughout the meeting highlighted both how far the field has come and how much opportunity remains ahead.

I am excited to continue advancing this work alongside an exceptional community of collaborators, mentors, and innovators committed to redefining what is possible for patients with cancer.”

Other articles featuring Yan Leyfman on OncoDaily.